5TRU
| Structure of the first-in-class checkpoint inhibitor Ipilimumab bound to human CTLA-4 | Descriptor: | Cytotoxic T-lymphocyte protein 4, Ipilimumab Fab heavy chain, Ipilimumab Fab light chain | Authors: | Ramagopal, U.A, Liu, W, Garrett-Thomson, S.C, Yan, Q, Srinivasan, M, Wong, S.C, Bell, A, Mankikar, S, Rangan, V.S, Deshpande, S, Bonanno, J.B, Korman, A.J, Almo, S.C. | Deposit date: | 2016-10-27 | Release date: | 2017-05-10 | Last modified: | 2023-10-04 | Method: | X-RAY DIFFRACTION (3 Å) | Cite: | Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab. Proc. Natl. Acad. Sci. U.S.A., 114, 2017
|
|
6V2O
| HLA-B*57:01 presenting the peptide ASLNLPAVSW | Descriptor: | ACETATE ION, Beta-2-microglobulin, MHC class I antigen, ... | Authors: | Maclachlan, B, Rossjohn, J, Vivian, J.P. | Deposit date: | 2019-11-25 | Release date: | 2020-05-20 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (1.27 Å) | Cite: | The molecular basis of how buried human leukocyte antigen polymorphism modulates natural killer cell function. Proc.Natl.Acad.Sci.USA, 117, 2020
|
|
6V2Q
| HLA-B*57:03 presenting the peptide LSSPVTKSF | Descriptor: | ACETATE ION, Beta-2-microglobulin, HLA-B alpha chain (B*5703GB), ... | Authors: | Maclachlan, B, Rossjohn, J, Vivian, J.P. | Deposit date: | 2019-11-25 | Release date: | 2020-05-20 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (1.6 Å) | Cite: | The molecular basis of how buried human leukocyte antigen polymorphism modulates natural killer cell function. Proc.Natl.Acad.Sci.USA, 117, 2020
|
|
6V3J
| KIR3DL1 in complex with HLA-B*57:03 presenting the peptide LSSPVTKSF | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Beta-2-microglobulin, HLA-B alpha chain (B*5703GB), ... | Authors: | Maclachlan, B, Rossjohn, J, Vivian, J.P. | Deposit date: | 2019-11-25 | Release date: | 2020-05-20 | Last modified: | 2024-10-09 | Method: | X-RAY DIFFRACTION (1.98 Å) | Cite: | The molecular basis of how buried human leukocyte antigen polymorphism modulates natural killer cell function. Proc.Natl.Acad.Sci.USA, 117, 2020
|
|
6V2P
| HLA-B*57:03 presenting the peptide ASLNLPAVSW | Descriptor: | ACETATE ION, Beta-2-microglobulin, DI(HYDROXYETHYL)ETHER, ... | Authors: | Maclachlan, B, Rossjohn, J, Vivian, J.P. | Deposit date: | 2019-11-25 | Release date: | 2020-05-20 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (1.3 Å) | Cite: | The molecular basis of how buried human leukocyte antigen polymorphism modulates natural killer cell function. Proc.Natl.Acad.Sci.USA, 117, 2020
|
|
7S7I
| Crystal structure of Fab in complex with MICA alpha3 domain | Descriptor: | 1,2-ETHANEDIOL, 2-acetamido-2-deoxy-beta-D-glucopyranose, Fab heavy chain, ... | Authors: | Lee, P.S, Strop, P. | Deposit date: | 2021-09-16 | Release date: | 2022-10-05 | Last modified: | 2023-10-25 | Method: | X-RAY DIFFRACTION (2.4 Å) | Cite: | Residue-Level Characterization of Antibody Binding Epitopes Using Carbene Chemical Footprinting. Anal.Chem., 95, 2023
|
|
7K80
| KIR3DL1*001 in complex with HLA-A*24:02 presenting the RYPLTFGW peptide | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, ACETATE ION, ARG-TYR-PRO-LEU-THR-PHE-GLY-TRP, ... | Authors: | MacLachlan, B.J, Rossjohn, J, Vivian, J.P. | Deposit date: | 2020-09-24 | Release date: | 2020-12-09 | Last modified: | 2024-10-09 | Method: | X-RAY DIFFRACTION (2.4 Å) | Cite: | The Role of the HLA Class I alpha 2 Helix in Determining Ligand Hierarchy for the Killer Cell Ig-like Receptor 3DL1. J Immunol., 206, 2021
|
|
7K81
| KIR3DL1*005 in complex with HLA-A*24:02 presenting the RYPLTFGW peptide | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, ARG-TYR-PRO-LEU-THR-PHE-GLY-TRP, Beta-2-microglobulin, ... | Authors: | MacLachlan, B.J, Rossjohn, J, Vivian, J.P. | Deposit date: | 2020-09-24 | Release date: | 2020-12-09 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | The Role of the HLA Class I alpha 2 Helix in Determining Ligand Hierarchy for the Killer Cell Ig-like Receptor 3DL1. J Immunol., 206, 2021
|
|
3EWJ
| Crystal structure of catalytic domain of TACE with carboxylate inhibitor | Descriptor: | (1S,3R,6S)-4-oxo-6-{4-[(2-phenylquinolin-4-yl)methoxy]phenyl}-5-azaspiro[2.4]heptane-1-carboxylic acid, ADAM 17, N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-3-methyl-L-valyl-N-(2-aminoethyl)-L-alaninamide, ... | Authors: | Orth, P. | Deposit date: | 2008-10-15 | Release date: | 2008-11-18 | Last modified: | 2023-09-06 | Method: | X-RAY DIFFRACTION (1.8 Å) | Cite: | Discovery of novel spirocyclopropyl hydroxamate and carboxylate compounds as TACE inhibitors. Bioorg.Med.Chem.Lett., 19, 2009
|
|